

TARGETING CANCER

New Science. New Cancer Therapies. New Hope.

Company Overview – July 2021

FORWARD-LOOKING STATEMENTS



This presentation contains forward-looking statements (including within the meaning of §21E of the U.S. Securities Exchange Act of 1934, as amended, and § 27A of the U.S. Securities Act of 1933, as amended). Forward-looking statements, which generally include statements regarding goals, plans, intentions and expectations, are based upon current beliefs and assumptions of Oncternal Therapeutics, Inc. ("Oncternal") and are not guarantees of future performance. Statements that are not historical facts are forward-looking statements, and include statements regarding the expected timing for achieving key milestones, including initiating ROR1 CAR-T studies and completing and announcing results of clinical trials of Oncternal's other product candidates, the anticipated market potential, duration of patent coverage, ability to obtain and maintain favorable regulatory designations, and potential accelerated approval pathways for Oncternal's product candidates and preclinical programs, and Oncternal's anticipated cash runway.

All forward-looking statements are subject to risks and uncertainties, including risks and uncertainties inherent in Oncternal's business, including risks associated with the clinical development and process for obtaining regulatory approval of Oncternal's product candidates such as potential delays in the commencement, enrollment and completion of clinical trials; the risk that results seen in a case study of one patient likely will not predict the results seen in other patients in the clinical trial; the risk that interim results of a clinical trial do not predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues, and as more patient data become available; and other risks described in Oncternal's filings with the U.S. Securities and Exchange Commission ("SEC"). Except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement. All forward-looking statements in this presentation are current only as of the date on which the statements were made. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in Oncternal's filings with the SEC.

Cirmtuzumab, TK216 and Oncternal's CAR-T targeting ROR-1 are investigational product candidates or preclinical programs that have not been approved by the U.S. Food and Drug Administration for any indication.

This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Oncternal has not independently verified such information and there can be no assurance as to its accuracy.

Corporate Highlights



CIRMTUZUMAB: POTENTIALLY FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING ROR1

- Ongoing clinical studies in MCL, CLL and breast cancer, and preclinical studies in additional cancer indications
- Interim Phase 1/2 results for cirmtuzumab + ibrutinib in MCL compare favorably to historical single-agent ibrutinib data
- Dialogue with FDA regarding potential accelerated approval study design in MCL

ROR1 CAR-T CELL THERAPY: AGREEMENTS WITH SHANGHAI PHARMA, KAROLINSKA INSTITUTET AND LENTIGEN

• In development to treat hematological malignancies and solid tumors

TK216: TARGETED ETS INHIBITOR

- Two durable complete responses in patients with metastatic relapsed/refractory Ewing sarcoma in ongoing Phase 1/2
- Additional opportunities in ETS-driven tumor indications

MULTIPLE DATA CATALYSTS EXPECTED IN NEXT 12 MONTHS

- Clinical data updates expected in MCL, CLL, breast cancer and Ewing sarcoma
- ROR1 CAR-T cell therapy expected to reach clinic in 1H 2022

EXPERIENCED MANAGEMENT AND BOARD OF DIRECTORS

Experienced Team







CFO

James Breitmeyer, MD, PhD **Richard Vincent** CEO, Founder, Director Genoa Sorrento Zavante BAVARIAN NORDIC HCRI 👽 Cadence Harvard Clinical Research Institute



élan



Salim Yazji, MD СМО 25 Baxter NOVARTIS Baxalta EXELIXIS SCALIMMUNE Johnson-Johnson



Gunnar Kaufmann, PhD CSO sorrento THERAPEUTICS

🚫 Scripps Research



Raj Krishnan PhD СТО 🚺 GILEAD

DYNAVAX AMGEN MERCK



General Counsel

LATHAM

LATHAM&WATKINS

-

Tang Capital

Management



Pablo Urbaneja SVP, Corporate Development







David Hale Co-founder Board Chairman micromet SANTARUS. ***CancerVax

GensiaSicor



Director

HEALTHCARE

Michael Carter, MD Jinzhu Chen, PhD

SPH 上海医药



Director





Daniel Kisner, MD Rosemary Mazanet, MD, PhD Director Director



Bill LaRue Director

***CancerVax



Xin Nakanishi, PhD Director



Director



Charles Theuer, MD, PhD **Robert Wills, PhD** Director

Roche





ONCT Corporate Presentation July 2021

Robust Pipeline – Novel Product Candidates in Multiple Indications



Product Candidate	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Modality	
	Mantle Cell Lymphoma (MCL)						
Cirmtuzumab	Chronic Lymphocytic Leukemia (CLL)				۵	OR1 mAb	
	Breast Cancer				Λ	OKI MAD	
	Ewing Sarcoma				γ		
TK216	Acute Myeloid Leukemia (AML)				ETS oncoprote	ein inhibitor	
	Prostate Cancer						
ROR1 CAR-T	Heme Cancers						
	Solid Tumors				ROR1 CAR-T cell	therapy	

ONCT Corporate Presentation July 2021



CIRMTUZUMAB

ROR1 monoclonal antibody

ROR1 (Receptor Tyrosine Kinase-Like Orphan Receptor 1) Compelling Tumor-Specific Target

- Expressed on most B-cell malignancies, including
 - Mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL)
- Expressed on many solid tumors
 - Increased ROR1 expression associated with more aggressive tumors, shorter PFS and OS
- ROR1 activity associated with aggressive phenotype
 - Invasion, metastasis, stem cell-like behavior, and resistance to treatment
- Subject of **recent large pharma acquisitions**
 - ROR1-ADCs: Merck (VelosBio), Boehringer (NBE)
- Oncternal ROR1 pipeline differentiated and advancing
 - Therapeutic antibody and cell therapy programs

ROR1 E	xpre	ssed	on	Multip	ole
Solid	and	Liqui	id T	umors	

MCL	95%
CLL	95%
Uterus	96%
Lymphoma	90%
Prostate	90%
Skin	89%
Pancreatic	83%
Adrenal	83%
Lung	77%
Breast	75%
Testicular	73%
Colon	57%
Ovarian	54%

Zhang 2012 AJP





Cirmtuzumab ROR1 mAb




Background

- High-affinity IgG1 humanized ROR1 mAb
- Patent coverage through 2033
- Supported by ~\$14M non-dilutive CIRM grant and Pharmacyclics product donation
- Cirmtuzumab is the mAb used in VLS-101 ADC
 - VelosBio spun out in 2018, acquired by Merck in 2020 for \$2.75B

Development status

- MCL: lead indication. P2 with ibrutinib (data: ASCO 2021)
 - Orphan Drug Designations for MCL and CLL
- CLL: P2 with ibrutinib (data: ASCO 2021); P1b with venetoclax
- HER-2 negative breast cancer: P1b with paclitaxel
- Investigating additional ROR1-expressing indications





Background

- CAR utilizing cirmtuzumab scFv for targeting
- ROR1 expression on many tumor types
- Potential safety and efficacy advantages
- VLS-101 data at ASH 2020 reported no off-tumor ROR1 organ toxicities

Development status


- Collaborations with Shanghai Pharma (China) and Karolinska Institutet. Manufacturing with Lentigen
- First-in-human dosing expected 1H 2022

Extensive Preclinical Research Supports Evaluation As Combination Therapy, Multiple Tumor Indications and Potential Safety Advantage




Synergism with Targeted Agents

- Synergistic with ibrutinib in CLL + MCL
 - ROR1-Wnt5a pathway not inhibited by ibrutinib




Yu 2017 Leukemia


• Synergistic with venetoclax (ABT-199)



Rassenti 2017 PNAS




Cirmtuzumab and paclitaxel are at least additive against TNBC PDX growth, and eliminate tumor forming cells *Zhang 2019 PNAS*




ROR1 Antagonism Suppresses Inflammation in CLL

- Cirmtuzumab blocks pro-inflammatory NF-kB signaling pathway in CLL cells
 - Potential explanation for safety profile observed in patients



Chen 2019 Blood





CIRLL Study:

- Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma
- MCL enrollment recently expanded
- Dialogue with FDA regarding potential accelerated approval study design in MCL

	STUDY DESIGN		
PART 1 (in CLL & MCL)	PART 2 (in CLL & MCL)	PART 3 (in CLL)	 Funded by CIRM
 DOSE-FINDING COHORT Cirmtuzumab at 2/4/8 & 16 mg/kg and 300 & 600 mg per dose Ibrutinib added after one month (420 mg CLL, 560 mg MCL qd po) 	 DOSE-EXPANSION COHORT Confirm Recommended Dosing Regimen (RDR) of cirmtuzumab (600 mg) + ibrutinib at approved dose (420 mg CLL, 560 mg MCL) 	 RANDOMIZED EFFICACY Cirmtuzumab + ibrutinib vs ibrutinib Primary endpoint: Complete Response rate 	 Collaboration with UC San Diego and CIRM Ibrutinib from Pharmacyclics/Abbvie
Enrolled	MCL Phase 2 enrolling CLL enrolled	Enrolled	



High response rates and durable responses observed in both MCL and CLL


	MCL evaluable=18	CLL evaluable=34
ORR, n (%)	15 (83.3)	32 (94.1)
CR, n (%)	7 (38.9)	5 (14.7)
PR, n (%)	8 (44.4)	27* (79.4)
SD, n (%)	2 (11.1)	2 (5.9)
PD, n (%)	1 (5.6)	0
Clinical Benefit Rate, n (%)	17 (94.4)	34 (100)
Median Duration of response in months (95% CI)	NE (11.93, NE)	NE

Data cut: 16APR2021; Evaluable MCL Part 1 & 2 patients (n=18); Evaluable CLL Part 1 & 2 patients (n=34); Patients were considered evaluable for response if they had 1-dose of cirmtuzumab and had 1-post baseline tumor assessment; CR- complete remission, PR- partial remission, SD- stable disease, PD- progressive disease; ORR- number and percent of patients that achieved CR or PR; Clinical benefit rate- number and percent of patients that achieved CR, PR or SD; NE- not estimable; *includes 1 partial remission with lymphocytosis

Oncternal Data 19MAY2021

Note: Rule et al., 2017 Br J Haem: ORR 66% and CR rate 20% for ibrutinib in MCL population with similar number of prior lines of therapy (pooled analysis across three third-party clinical studies).





Data cut: 16APR2021; Evaluable MCL Part 1 & 2 patients (n=18); Patients were considered evaluable for response if they had 1-dose of cirmtuzumab and had 1-post baseline tumor assessment; SPD= sum of product of diameters; Number under bars represent baseline SPD; NE=not estimable

Note: Rule et al., 2017 Br J Haem: median PFS 12.8 months for ibrutinib in MCL population with similar number of prior lines of therapy (pooled analysis across three third-party clinical studies).

ONCT Corporate Presentation July 2021



Responses rates are favorable in patients with high-risk factors associated with difficult to treat disease, including prior ibrutinib (4CR/4PR)

	All MCL evaluable=18	Ki-67 ≥30% n=9	>1 prior systemic regimen n=9
Overall Response Rate (ORR), n (%)	15 (83.3)	8 (88.9)	8 (88.9)
CR, n (%)	7 (38.9)	3 (33.3)	5 (55.6)
PR, n (%)	8 (44.4)	5 (55.6)	3 (33.3)
SD, n (%)	2 (11.1)	0	1 (11.1)
PD, n (%)	1 (5.6)	1 (11.1)	0
Clinical Benefit Rate, n (%)	17 (94.4)	8 (88.9)	9 (100)
Median Duration of Response in months (95% CI)	NE (11.93, NE)	13.84 (8.66, NE)	NE (8.66, NE)
Median Time to First Response in months (95% CI)	2.79 (2.66, 2.79)	2.79 (2.66, 2.79)	2.77 (1.84, 2,82)
Median Time to CR in months (95% CI)	2.79 (1.84, 8.20)	2.79 (2.66, 11.02)	2.79 (1.84, 8.20)


Data cut: 16APR2021; CR- complete remission, PR- partial remission, SD- stable disease, PD- progressive disease; ORR- number and percent of patients that achieved CR or PR; Clinical benefit rate- number and percent of patients that achieved CR, PR or SD; NE- not estimable; Time to response analyses- Part 1 first scans were done at day 28, Part 2 first scans were done at 3 months

Oncternal Data 19MAY2021

Note: Rule et al., 2017 Br J Haem: median PFS 12.8 months for ibrutinib in MCL population with similar number of prior lines of therapy (pooled analysis across three third-party clinical studies).

Cirmtuzumab + Ibrutinib Interim Clinical Results in MCL (ASCO 2021) Compare Favorably to Historical Single-Agent Ibrutinib Data





Note: Data presented are from separate studies and such data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of the combination of cirmtuzumab and ibrutinib compared to single-agent ibrutinib; NE= not estimable


ONCT Corporate Presentation July 2021

Cirmtuzumab + Ibrutinib Data Update at ASCO 2021




94% ORR and median PFS not reached in CLL

Best % Tumor Reduction CLL Parts 1 & 2



Data cut: 16APR2021; Evaluable CLL Part 1 & 2 patients (n=34); Patients were considered evaluable for response if they had 1-dose of cirmtuzumab and had 1-post baseline tumor assessment; SPD= sum of product of diameters; Number under bars represent baseline SPD; NE= not estimable



Progression-Free Survival

Oncternal Data 19MAY2021

ONCT Corporate Presentation July 2021



MCL:

- Clinical activity compares favorably to published singleagent ibrutinib data*
 - ORR 83% (15/18)
 - CR rate 39% (7/18)
 - CRs durable for 8-30+ months
 - Clinical benefit 94% (17/18)
 - Median PFS and OS not reached, regardless of prior number of therapies, after a median follow-up of 18.9 months
- Encouraging clinical activity in high-risk sub-populations
 - Ki-67 levels ≥30% (n=9): 89% ORR (3 CR, 5 PR)
 - > 1 prior systemic therapy (n=9): 89% ORR (5 CR, 3 PR)
 - Prior ibrutinib (n=4): **100%** ORR (2 CR, 2 PR)
 - Prior SCT or CAR-T (n=6): **100%** ORR (4 CR, 2 PR)

CLL/SLL:

- The combination of cirmtuzumab plus ibrutinib is a welltolerated and active regimen in CLL
 - Updated Part 1 & 2 results:
 - ORR 94% (32/34)
 - CR rate 15% (5/34); 3 with clinical CR
 - Clinical Benefit 100% (34/34)
 - One patient achieved CR durable for >17 months off all therapy
 - Median PFS and OS not reached after median follow-up of 22.1 months
 - Updated randomized cohort (Part 3) results to be presented 2H 2021

No additional toxicity when cirmtuzumab is combined with ibrutinib

- The combination of cirmtuzumab plus ibrutinib has been well tolerated, with treatment emergent adverse events and hematologic abnormalities consistent with, or slightly lower than those reported for ibrutinib alone
 - There have been no dose-limiting toxicities and no serious adverse events attributed to cirmtuzumab alone

*Historical data with single-agent ibrutinib in MCL population with similar distribution of prior lines of therapy reported overall ORR 66% and CR rate 20% (Rule et al. 2017 Br J Haem); such data may not be directly comparable due to differences in study protocols, conditions and patient populations.

ONCT Corporate Presentation July 2021


16

HER2-negative Breast Cancer: Cirmtuzumab + Paclitaxel Interim Data Presented at AACR: ORR 57%



20% increase

·30% decrease



* BROR-05 and BROR-09 had stable disease with targeted lesion response, overall response was PD due to new or worsening nontargeted lesions. ** BROR-03 and BROR-21 were still on treatment as of 2/26/2021. BROR-01 was not included in the graph due to progressive disease symptoms 3 weeks after treatment initiation requiring study discontinuation before first imaging assessment.

Historical reported weekly paclitaxel ORR ~30%⁽¹⁾


(1) Weekly paclitaxel ORR: 21% - Miller 2007 NEJM, 32-42% - Seidman 2008 JCO, 32% - Kim 2017 Lancet Oncol , 29% - Schmid 2019 JCO. Disclaimer: Results not based on head-to-head clinical studies. The results from historical trials not directly comparable and do not imply a clinical benefit of cirmtuzumab + paclitaxel over paclitaxel alone.

Investigator sponsored trial at UC San Diego, Barbara Parker & Rebecca Shatsky

- Now fully enrolled
- Patients with HER2 negative, metastatic or locallyadvanced unresectable breast cancer
- Cirmtuzumab 600 mg/month + paclitaxel weekly at 80 mg/m2 IV
- 15 patients, median of 6 prior therapies for metastatic disease
 - 4/15 patients had triple negative breast cancer
- Adverse events (AEs) were consistent with known safety profile of paclitaxel alone
- 100% of tumors expressed ROR1
 - (8/8 fresh or archival tissue)
- 57% objective response rate
 - Similar to previous interim data reported
 - 8 PRs among 14 evaluable patients
 - One PR durable for 52 weeks, ~6 months on cirmtuzumab alone
 - 4 additional patients had stable disease Shatsky 2021 AACR

ClinicalTrials.gov Identifier: NCT02776917

Cirmtuzumab Consolidation for Treatment of CLL Patients with Detectable MRD on Venetoclax



• Following 6 months of cirmtuzumab + venetoclax, patients are assessed for MRD in the blood/marrow.

Screening Dx of CLL/SLL At least 1 year of venetoclax Detectable MRD in	Cirmtuzumab 600 mg IV day 1, 15, 29, then q28d (7 total infusions)	Primary Endpoint uMRD in marrow at end of combination therapy	
blood or marrow (> 0.01%)	Venetoclax 400 mg PO daily		
Primary Feasibility Endpoint: Undetectable MRD (uMRD) rate after Cirmtuzumab + Venetoclax	 Main inclusion criteria: CLL or SLL Detectable CLL (> 0.01% CLL cells in the blood or marrow) 	 <u>Statistical Considerations</u> Success rate of 25% uMRD considered compelling. Success rate of < 5% would 	
<u>Secondary and Exploratory</u> <u>Endpoints:</u> Safety, time to next treatment, gene expression changes	 Must have received at least 12 months of venetoclax. (may be receiving venetoclax at the time of screening and study entry.) 	 be considered not compelling. n =16, 80% power to reject H_{0,} α < 5% 	



ROR1 CAR-T Program



Current CAR-T Cell Therapy Weaknesses

Treatment failures

- Resistance to CAR-T therapy, frequently due to mutations, downregulation or loss of the non-essential target antigen
 - For example: CD19, BCMA

Safety concerns

• CAR-T cell therapy safety issues related to activation by normal cells expressing the target antigen

Strengths of Targeting ROR1

Potential for fewer antigen negative relapses

- ROR1 expression associated with aggressive tumor phenotype
- ROR1 mutation or loss might render cancer cells less aggressive and susceptible to chemotherapy

Potential safety advantages

- No crossreactivity of cirmtuzumab to normal human tissues in IND-enabling studies
- No serious adverse events related to cirmtuzumab-only observed in clinical studies
- ROR1 ADC VLS-101 no unusual organ toxicity*





DEVELOPMENT STATUS

- Utilizing cirmtuzumab scFv as targeting component
- Preclinical data in hematologic and solid tumor models
- IND-enabling activities initiated
- **Karolinska** Institutet R&D collaboration for ROR1-targeting CAR-T and CAR-NK cell therapies
- Agreement with Lentigen for lentivirus production and manufacturing
- Shanghai Pharma collaboration for clinical trials


OPPORTUNITY

- Selective targeting strategy across multiple tumor indications based
- First human proof-of-concept in hematological cancers, then expansion into solid tumors





Bioluminescence imaging of mice inoculated with MEC1-ROR1 cells and with ROR1 CAR T-cells. Animals treated with CAR-T cells had reduced disease burden compared to controls.



Bioluminescence imaging of MEC1-ROR1 cells following treatment with ROR1 CAR-T cells. Mice treated with 3e6 CAR-T reduced the leukemic burden to background levels by day 30 and controlled disease for remainder of study. Animals in the control groups (untreated, ATC or lower 1e6 dose) had to be sacrificed on day 20.

Prussak 2020 ASCO SITC

ONCT Corporate Presentation July 2021

ONCTERNAL

therapeutics'





- Demonstrate evidence of clinical safety and activity
- Reduce technology risk: autologous, heme indication susceptible to CAR-T cell therapy
- SPH collaboration for clinical trials
- If successful, rapidly initiate clinical development in U.S. or Europe





Develop next-generation cell therapies targeting ROR1

- Introduce cutting-edge cell therapy technologies
- Partnerships
- Allogeneic CAR-T and CAR-NK
- Solid tumors



a Miltenyi Biotec Company



TK216

Targeted ETS Oncoprotein Inhibitor

OPPORTUNITY


- Fast-to-market strategy in Ewing sarcoma (>95% ETS+)
 - Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status granted by FDA; Potentially Pediatric Voucher eligible
- Significant market potential in other cancers with ETS alterations
- COM patent coverage through 2037

MECHANISM OF ACTION

- Novel small molecule inhibitor of ETS family oncoproteins
 - Designed to prevent/disrupt formation of transcriptionally-active protein complex
- ETS transcription factors regulate many target genes implicated in cancer development and progression

DEVELOPMENT STATUS

 Encouraging activity in ongoing expansion cohort for relapsed/refractory Ewing sarcoma. **ETS** = **E**26 **T**ransformation-**S**pecific oncogene family



Erkizan NatureMed 2009



Unmet Medical Need Relapsed / Refractory Ewing Sarcoma

- Nearly all Ewing sarcoma driven by translocations of ETS family oncogenes (EWS-FLI1 85-90%, EWS-ERG ~10%)
 - ETS transcription factors regulate many genes implicated in cancer development and progression
- Orphan disease, second most common pediatric bone tumor
 - U.S. incidence ~430 p.a.⁽¹⁾
 - U.S. prevalence ~4,000⁽¹⁾
- Median age at diagnosis 15 years
- No standard second-line treatment and poor prognosis
 - Metastatic EWS: 5-year OS ~30%
 - Recurrent EWS: 5-year OS ~10-15%

ETS = E26 Transformation-Specific oncogene family



(1) Incidence 1.3 per million, prevalence 12 per million – SEER data "ICD-0-3/WHO 2008 Ewing Tumor", accessed

January 3, 2020; NCI Ewing Sarcoma Treatment (PDQ), accessed September 11, 2019; Company analysis



Phase 1/2 Study of TK216 in Patients with Relapsed/Refractory Ewing Sarcoma: Early Evidence of Clinical Activity, Enrolling Expansion Cohort

- 3+3 dose and schedule escalation cohorts completed
 - Total 68 patients with relapsed/refractory Ewing sarcoma treated with TK216
 - Median number of prior theories: 3 (range: 1, 9)
 - Recommended Phase 2 dose (RP2D) established: TK216 200 mg/m²/day for 14 days + vincristine 0.75 mg/m² day 1
- <u>Safety</u>: generally well-tolerated, with dose limiting toxicity of manageable myelosuppression and no obvious off-target toxicity
- <u>PK</u>: drug plasma levels at RP2D exceeded those associated with anti-cancer activity in preclinical models
- <u>Activity at RP2D</u>: 45% disease control rate among 31 evaluable patients ⁽¹⁾
 - 2 durable complete responses (one surgical CR): no evidence of disease at 24+ months and 14+ months on study
- Enrollment in Phase 2 expansion cohort is ongoing



TK216 Demography & Baseline Characteristics



	All Patients n=68	Cohort 9 & Expansion (RP2D) n=39
Median Age (years)	27.0 (11.0, 77.0)	27.0 (11.0, 77.0)
Male, n (%)	43 (63.2)	25 (64.1)
ECOG* 0-1, n (%)	52 (96.3)	29 (93.5)
Median time from diagnosis to study start (years)	3.4 (0.4, 18.0)	3.4 (0.4, 18.0)
Prior surgery, n (%)	53 (77.9)	32 (82.1)
Prior radiotherapy, n (%)	57 (83.8)	34 (87.2)
Median number of prior systemic treatments	3.0 (1.0, 9.0)	3.0 (1.0, 8.0)
Metastases at study entry, n (%)	67 (98.5)	39 (100)
Bone only	6 (8.8)	2 (5.1)
Lung only	31 (45.6)	21 (53.8)
Bone and Lung only	10 (14.7)	8 (20.5)
Other location	20 (29.4)	8 (20.5)


Data Cut: 16APR2021; *ECOG (Eastern Cooperative Oncology Group) performance score was evaluated in 54 and 31 all treated and Cohort 9 & Expansion patients, percentage is based on number of patients with ECOG evaluated; Median estimates are shown with (min, max)

Population: Heavily pre-treated and high disease burden


TK216 Overall Best Clinical Response and PFS in R/R Ewing Sarcoma



Notable responses and disease control observed at the RP2D



Data cut: 16APR2021; Patients were considered evaluable for response if they completed 1-cycle of treatment and had 1-post baseline tumor assessment; CR- complete response, PR- partial response, SD- stable disease, PD- progressive disease; ORR- number and percent of patients that achieved CR or PR; DCR- number of patients that achieved CR, PR or SD; * Two confirmed CRs with no PD at data cut; ** Unconfirmed PR observed in target lesion at Cycle 4 then PD observed at Cycle 6 in non-target lesions



Data cut: 16APR2021; PFS is defined as time from enrollment to objective tumor progression via RECIST 1.1, or death from any cause, which ever occurs first; Evaluable patients were used for PFS analyses

Case Study: First Sustained Complete Response with TK216 in Patient with Metastatic Relapsed/Refractory Ewing Sarcoma



Patient background

- 19-year-old male. Initially diagnosed with metastatic Ewing ٠ sarcoma involving the clavicle and lungs
- Prior treatment included VDC/IE, surgery, radiation, irinotecan/ temozolomide, bevacizumab, pazopanib
- Progressing with enlarging lung metastases when enrolled in TK216 clinical trial
- Enrolled in Phase 1 study of TK216 at MSKCC in 2019

Treatment and outcome

All target lesions resolved

- Received TK216 in final dose-finding cohort (200 mg/m²/day) ٠
- **Resolution of target lesions after two cycles of single-agent TK216** ٠
 - Treatment well tolerated, with minimal myelosuppression
 - Vincristine added starting in third cycle
- Residual non-target 7 mm lung lesion excised after 6 cycles of therapy, leading to surgical complete remission
- Treatment ongoing, no evidence of disease at >24 months on study






Baseline


ONCT Corporate Presentation July 2021

Case Study: Second Complete Response with TK216 in Patient with Metastatic Relapsed/Refractory Ewing Sarcoma



- Patient: 51-year-old with Ewing sarcoma diagnosed June 2018
 - 10-cm tumor near the right kidney and multiple lung metastases
- Extensive prior treatment:
 - Chemotherapy: VDC/IE, high-dose ifosfamide
 - Surgery: right nephrectomy and vascular reconstruction
- Recurrence prior to enrollment: Multiple new and enlarging lung lesions
- **TK216:** Enrolled at MD Anderson Cancer Center in January 2020
 - Treated at RP2D (TK216 200 mg/m²/day for 14 days + vincristine 0.75 mg/m² day 1)
 - Myelosuppression in Cycle 1, did not recur in Cycle 2 with growth factor support and no TK216 dose reduction
- Clinical response:
 - Deep partial response after 2 cycles, with 90% reduction of target lesions
 - Complete response after 6 cycles of therapy
- Treatment ongoing, with no evidence of disease at >14 months on study






31




Acute Myeloid Leukemia (AML)

- ETS family proteins <u>overexpressed</u> in ~30% AML cases
- ETS2 overexpression associated w/ shorter OS




- Sensitivity of AML cell lines to TK216 was proportional to level of ETS overexpression
- ETS inhibition using TK216 precursor prolonged survival in EWS-FLI1 transgenic




Prostate Cancer

 55% of men with advanced prostate cancer carry <u>ETS family gene fusion</u> TMPRSS2-ERG associated with androgen resistance and poor clinical outcomes

TMPRSS2 and ERG are located on chromosome 21




 ETS inhibition using TK216 precursor demonstrated anti-tumor activity in human prostate cancer xenograft model



Diffuse Large B Cell Lymphoma (DLBCL)

- ETS proteins overexpressed in DLBCL
- ETS family member genes are essential for activated B-cell-like (ABC) DLBCL and germinal center B-cell type (GCB) DLBCL
- Synergy with lenalidomide and venetoclax shown in preclinical models
- Single agent TK216 and combo therapy demonstrated potent anti-tumor activity in DLBCL xenograft model





BUSINESS & FINANCIALS

\$3,500,000

\$2,500,0



Description	Ticker: ONCT (Nasdaq)
Cash & Cash Investments @ March 31, 2021	\$111M
Cash Runway into 2023 Debt	\$0M
Capitalization:	
Common Shares Outstanding	49.4M
Options / Warrants in the Money @ Mar 31, $2021^{(1)}$	7.7M
Fully Diluted	57.1M
Non-Dilutive Support	
 CIRM Grant for CIRLL Study 	~\$14M
 Ibrutinib CTM for CIRLL Study 	Expanded Supply
	Agreement



4Q 2021

4Q 2021

4Q 2021

4Q 2021

Fully Enrolled

Cirmtuzumab

- MCL clinical data update for ongoing Phase 1/2
- CLL clinical data update for ongoing Phase 1/2
- HER2-negative breast cancer clinical data update for ongoing Phase 1b (IST)
- Preclinical data in additional ROR1-expressing tumors
- ROR1 CAR-T cell therapy first-in-human dosing
 1H 2022

• TK216

- Ewing sarcoma Phase 1/2 expansion cohort data update 4Q 2021
- Preclinical data in additional ETS-driven tumors

Corporate Highlights



CIRMTUZUMAB: POTENTIALLY FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING ROR1

- Ongoing clinical studies in MCL, CLL and breast cancer, and preclinical studies in additional cancer indications
- Interim Phase 1/2 results for cirmtuzumab + ibrutinib in MCL compare favorably to historical single-agent ibrutinib data
- Interim Phase 1b results for cirmtuzumab + paclitaxel in HER2^{neg} breast cancer continue to show encouraging ORR
- Dialogue with FDA regarding potential accelerated approval study design in MCL

ROR1 CAR-T CELL THERAPY: AGREEMENTS WITH SHANGHAI PHARMA, KAROLINSKA INSTITUTET AND LENTIGEN

• In development to treat hematological malignancies and solid tumors

TK216: TARGETED ETS INHIBITOR

- Two durable complete responses in patients with metastatic relapsed/refractory Ewing sarcoma in ongoing Phase 1/2
- Additional opportunities in ETS-driven tumor indications

MULTIPLE DATA CATALYSTS EXPECTED IN NEXT 12 MONTHS

- Clinical data updates expected in MCL, CLL, breast cancer and Ewing sarcoma
- ROR1 CAR-T cell therapy expected to reach clinic in 1H 2022

EXPERIENCED MANAGEMENT AND BOARD OF DIRECTORS